Physician profile
Daniel A Olsen
NPI 1366973950
$3,284.82
in general payments reported to CMS, 2019-2025
31 companies · $591 in 2025
The $591 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $654 · 2021: $329 · 2022: $321 · 2023: $833 · 2024: $556 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,980.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $671.65 | 2020-2024 | |
| Axonics, INC. | $591.00 | 2022-2024 | Axonics |
| Boston Scientific Corporation | $464.14 | 2020-2025 | Spaceoar Vue System - 10ml |
| Urogen Pharma, INC. | $217.13 | 2021-2025 | Jelmyto |
| Sumitomo Pharma America, INC. | $172.52 | 2023-2025 | Orgovyx |
| Histosonics, INC. | $170.62 | 2025 | |
| Calyxo, INC. | $150.38 | 2025 | Cvac Aspiration System |
| Abbvie INC. | $84.80 | 2024 | |
| Myriad Genetic Laboratories, INC. | $65.69 | 2023 | Prolaris |
| Myovant Sciences INC. | $59.02 | 2022 | |
| Pfizer INC. | $58.02 | 2023-2024 | |
| Janssen Biotech, INC. | $57.42 | 2023-2024 | Erleada, Akeega |
| Merck Sharp & Dohme LLC | $55.91 | 2023-2025 | Keytruda, Lynparza |
| Foundation Medicine, INC. | $55.15 | 2023 | Foundationone Cdx |
| Tolmar, INC. | $52.62 | 2023-2025 | Jatenzo, Eligard |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $41.83 | 2021-2024 | |
| Medtronic, INC. | $40.98 | 2021 | |
| Telix Pharmaceuticals | $35.11 | 2024-2025 | Illuccix |
| Coloplast Corp | $31.95 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $22.70 | 2025 | Lynparza |
| Teleflex LLC | $20.94 | 2023 | Urolift |
| E.R. Squibb & Sons, L.L.C. | $18.16 | 2025 | Opdivo |
| Astellas Pharma US INC | $18.07 | 2023 | Myrbetriq |
| 180 Medical, INC. | $18.02 | 2024 | Gentlecath |
| Accord Healthcare, INC. | $17.66 | 2025 | |
| Argon Medical Devices, INC. | $17.56 | 2025 | Clot Management |
| Ferring Pharmaceuticals INC. | $17.11 | 2024 | Adstiladrin |
| Kowa Pharmaceuticals America, INC. | $15.94 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $14.92 | 2022 | |
| Endo Pharmaceuticals INC. | $14.29 | 2023 | Aveed, Xiaflex |
| Sun Pharmaceutical Industries INC. | $13.51 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Olsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.